JHM Biopharma nets another CNY 100 Mn in its Series A round only 3 months after its A1 financing
Biotechnology company JHM Biopharma (Chinese: 君合盟) announced that it had completed another CNY 100 million in Series A+ round only 3 months after its completion of Series A1 round. This round was co-led by Guangdian Capital (Chinese: 光点资本) and 3E Bioventures Capital (Chinese: 本草资本). WinX Capital (Chinese: 凯乘资本) acted as an exclusive financial adviser. Only 3 months before, JHM Biopharma completed a CNY 100 million in a Series A1 round to support its biologic products for childhood genetic diseases, anti-aging, anti-virus and new biological materials.
The funds raised in this round will be used mainly for the R&D of drug candidates pipelines, the expansion of reserve pipeline and the construction of a commercial manufacturing base with GMP facility requirements.
Founded in 2020, JHM Biopharma is a biotechnology company with the R&D pipeline structured around metabolism, medical aesthetics and other large market protein drugs. Its lead products include recombinant botulinum toxin type A and growth hormone. Moreover, it has built a nearly 8,000-square-meter GMP warehouse at Hangzhou Medical Port, which can meet the production and commercialization needs of the company's product pipeline.
Sino Biological (Chinese: 义翘科技), ACRO Biosystems (Chinese: 百普赛斯), and NovoProtein (Chinese: 近岸蛋白) are JHM Biopharma's competitors.